Core Viewpoint - Yifang Bio experienced a stock price decline of 2.07% on December 23, with a current price of 29.38 CNY per share and a total market capitalization of 16.992 billion CNY [1] Group 1: Stock Performance - Yifang Bio's stock has increased by 120.90% year-to-date, with a slight increase of 0.44% over the last five trading days and an 8.41% increase over the last 20 days, but a decline of 12.84% over the last 60 days [1] - The company has appeared on the "Dragon and Tiger List" four times this year, with the most recent appearance on October 31, where it recorded a net buy of -392.836 million CNY [1] Group 2: Financial Performance - For the period from January to September 2025, Yifang Bio reported a revenue of 30.8935 million CNY, representing a year-on-year growth of 61.27%, while the net profit attributable to shareholders was -181 million CNY, showing a year-on-year increase of 40.59% [2] - As of September 30, 2025, the number of shareholders increased by 26.17% to 12,400, while the average circulating shares per person decreased by 17.52% to 33,810 shares [2] Group 3: Shareholder Structure - The largest circulating shareholder is Hong Kong Central Clearing Limited, holding 16.2161 million shares, an increase of 8.162 million shares compared to the previous period [2] - New entrants among the top ten circulating shareholders include Ping An Medical Health Mixed A and Yongying Medical Innovation Selected Mixed Initiation A, holding 6.2749 million shares and 7.9219 million shares, respectively [2]

Core Viewpoint - The stock of Shuyou Shen experienced a decline of 2.01% on December 23, with a current price of 26.88 yuan per share and a total market capitalization of 12.843 billion yuan. The company has seen significant fluctuations in its stock price throughout the year, with a year-to-date increase of 262.75% but a recent decline over the past 20 and 60 days [1]. Financial Performance - For the period from January to September 2025, Shuyou Shen reported a revenue of 181 million yuan, representing a year-on-year decrease of 30.82%. The net profit attributable to the parent company was -30.6895 million yuan, a decline of 227.71% compared to the previous year [2]. Shareholder Information - As of September 30, 2025, the number of shareholders for Shuyou Shen was 46,500, an increase of 46.97% from the previous period. The average number of circulating shares per shareholder was 9,745, which decreased by 31.98% [2]. Dividend Distribution - Since its A-share listing, Shuyou Shen has distributed a total of 771 million yuan in dividends. However, there have been no dividend distributions in the last three years [3]. Institutional Holdings - Among the top ten circulating shareholders as of September 30, 2025, Xingshan He Run Mixed A ranked as the third-largest shareholder with 12.2691 million shares, a decrease of 3.4519 million shares from the previous period. Xingshan He Yi Mixed A ranked fifth with 9.3396 million shares, an increase of 3.3875 million shares [3].

Investment Rating - The report does not explicitly state an investment rating for the industry [2]. Core Insights - The pathology business is entering a fast track with the National Healthcare Security Administration issuing guidelines for pricing projects in pathology services, focusing on biopsy sampling, sample processing, and digitalization of pathology data, which is expected to enhance the application of AI in the field [3][11]. - The influenza activity has peaked across the board, with reported cases in southern provinces at 9.7%, down from 11.2% the previous week, but higher than the same period in previous years [3][11]. Market Weekly Review - The pharmaceutical and biotechnology sector fell by 0.14% from December 15 to December 19, outperforming the Wind All A index (-0.15%) and the CSI 300 index (-0.28%). The rebound was weak, with segments like pharmaceutical distribution (5.59%), offline pharmacies (4.69%), and hospitals (4.15%) leading gains, while chemical preparations (-2.1%), vaccines (-0.87%), and medical R&D outsourcing (-0.87%) lagged [3][8]. - Notable stock performances included Huaren Health (55.9%), Luyuan Pharmaceutical (36.8%), and Shuyupingmin (35.7%) with significant gains, while *ST Changyao (-24%), Yipinhong (-23.7%), and Rejing Biology (-16.5%) faced substantial declines [3][11]. Industry News and Key Company Announcements - The National Healthcare Security Administration's guidelines for pathology services are expected to drive high-quality development in the sector and create new scenarios for AI-assisted technology applications [11]. - Significant collaborations and approvals were reported, including Shanghai Jinmante's partnership with Jiangsu Kangning Jerey for a breakthrough therapy designation from the FDA for JSKN003, and Novo Nordisk's submission of a marketing application for CagriSema, which showed a weight loss of 22.7% over 68 weeks in clinical trials [12][13]. - Fosun Pharma's subsidiary received FDA approval to initiate a Phase I clinical trial for HLX18, a biosimilar to Nivolumab, targeting various cancers [13][14].

截至9月30日，通化金马股东户数3.82万，较上期减少3.20%；人均流通股25266股，较上期增加3.31%。 2025年1月-9月，通化金马实现营业收入8.92亿元，同比减少7.88%；归母净利润2496.35万元，同比增长 4.35%。 分红方面，通化金马A股上市后累计派现2.10亿元。近三年，累计派现0.00元。 机构持仓方面，截止2025年9月30日，通化金马十大流通股东中，创新药（159992）位居第七大流通股 东，持股919.30万股，相比上期增加8.78万股。南方中证1000ETF（512100）位居第八大流通股东，持 股884.16万股，相比上期减少9.23万股。香港中央结算有限公司位居第九大流通股东，持股726.71万 股，相比上期减少150.84万股。华夏中证1000ETF（159845）位居第十大流通股东，持股525.31万股， 为新进股东。 今年以来通化金马已经2次登上龙虎榜，最近一次登上龙虎榜为9月11日，当日龙虎榜净买入1.42亿元； 买入总计5.44亿元 ，占总成交额比29.22%；卖出总计4.02亿元 ，占总成交额比21.59%。 资料显示，通化金马药业集团股份有限公司位于吉 ...

益方生物所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：基金重仓、融资融券、 中盘、抗癌药物、年度强势等。 截至9月30日，益方生物股东户数1.24万，较上期增加26.17%；人均流通股33810股，较上期减少 17.52%。2025年1月-9月，益方生物实现营业收入3089.35万元，同比增长61.27%；归母净利润-1.81亿 元，同比增长40.59%。 机构持仓方面，截止2025年9月30日，益方生物十大流通股东中，香港中央结算有限公司位居第一大流 通股东，持股1621.61万股，相比上期增加816.20万股。汇添富创新医药混合A（006113）位居第三大流 通股东，持股1031.11万股，相比上期增加34.92万股。中欧医疗健康混合A（003095）位居第六大流通 股东，持股814.77万股，相比上期减少94.47万股。永赢医药创新智选混合发起A（015915）位居第七大 流通股东，持股792.19万股，为新进股东。平安医疗健康混合A（003032）位居第十大流通股东，持股 627.49万股，为新进股东。睿远成长价值混合A（007119）退出十大流通股东之列。 益方生物今年以来股价涨1 ...

Core Insights - Heng Rui Medicine's stock price increased by 2.00% on December 19, reaching 61.20 CNY per share, with a total market capitalization of 406.197 billion CNY [1] - The company has seen a year-to-date stock price increase of 33.92%, but a decline of 3.29% in the last five trading days [1] Company Overview - Jiangsu Heng Rui Medicine Co., Ltd. is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology [2] - The company's product portfolio includes anti-tumor drugs, analgesics, and contrast agents, with applications across various diseases [2] - Main business revenue composition: 86.88% from product sales, 12.63% from licensing income, and 0.49% from other sources [2] Financial Performance - As of September 30, Heng Rui Medicine reported a revenue of 23.188 billion CNY for the first nine months of 2025, a year-on-year increase of 14.85% [3] - The net profit attributable to shareholders for the same period was 5.751 billion CNY, reflecting a year-on-year growth of 24.50% [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 397,300, with an average of 16,058 circulating shares per person [3] - The company has distributed a total of 9.303 billion CNY in dividends since its A-share listing, with 3.568 billion CNY in the last three years [4] - Major shareholders include Hong Kong Central Clearing Limited and China Securities Finance Corporation, with some reductions in shareholdings noted [4]

12月19日，艾力斯盘中上涨2.02%，截至10:02，报101.98元/股，成交5559.07万元，换手率0.12%，总市 值458.91亿元。 资金流向方面，主力资金净流出105.51万元，大单买入722.43万元，占比13.00%，卖出827.94万元，占 比14.89%。 分红方面，艾力斯A股上市后累计派现6.53亿元。 机构持仓方面，截止2025年9月30日，艾力斯十大流通股东中，香港中央结算有限公司位居第四大流通 股东，持股2094.71万股，相比上期增加1056.93万股。中欧医疗健康混合A（003095）位居第八大流通 股东，持股859.51万股，相比上期减少55.75万股。易方达上证科创板50ETF（588080）位居第九大流通 股东，持股828.14万股，相比上期减少103.11万股。华夏上证科创板50成份ETF（588000）位居第十大 流通股东，持股796.44万股，相比上期减少445.65万股。 责任编辑：小浪快报 资料显示，上海艾力斯医药科技股份有限公司位于上海市浦东新区周浦镇凌霄花路268号，成立日期 2004年3月22日，上市日期2020年12月2日，公司主营业务涉及创新药物的 ...

海思科今年以来股价涨59.34%，近5个交易日跌3.93%，近20日跌6.48%，近60日跌4.02%。 12月19日，海思科盘中上涨2.04%，截至09:54，报52.55元/股，成交1620.64万元，换手率0.06%，总市 值588.52亿元。 资金流向方面，主力资金净流出43.16万元，大单买入150.72万元，占比9.30%，卖出193.89万元，占比 11.96%。 截至9月30日，海思科股东户数1.29万，较上期增加12.87%；人均流通股37342股，较上期减少11.40%。 2025年1月-9月，海思科实现营业收入33.00亿元，同比增长19.95%；归母净利润2.95亿元，同比减少 22.66%。 分红方面，海思科A股上市后累计派现36.73亿元。近三年，累计派现6.87亿元。 机构持仓方面，截止2025年9月30日，海思科十大流通股东中，中欧医疗健康混合A（003095）位居第 五大流通股东，持股2139.75万股，相比上期增加12.12万股。香港中央结算有限公司位居第六大流通股 东，持股1806.01万股，相比上期增加988.04万股。工银前沿医疗股票A（001717）位居第七大流通股 ...

资料显示，深圳信立泰药业股份有限公司位于广东省深圳市福田区深南大道6009号车公庙绿景广场主楼 (B座)37层，成立日期1998年11月3日，上市日期2009年9月10日，公司主营业务涉及药品、医疗器械产 品的研发、生产、销售。主营业务收入构成为：制剂81.69%，器械8.54%，原料7.17%，其他2.59%。 12月18日，信立泰盘中下跌2.03%，截至13:59，报55.55元/股，成交1.50亿元，换手率0.24%，总市值 619.28亿元。 资金流向方面，主力资金净流出572.07万元，特大单买入106.02万元，占比0.71%，卖出358.83万元，占 比2.39%；大单买入2595.82万元，占比17.31%，卖出2915.08万元，占比19.44%。 信立泰今年以来股价涨82.55%，近5个交易日跌6.15%，近20日跌9.04%，近60日涨5.59%。 今年以来信立泰已经2次登上龙虎榜，最近一次登上龙虎榜为6月17日，当日龙虎榜净买入-4198.85万 元；买入总计1.14亿元 ，占总成交额比12.79%；卖出总计1.56亿元 ，占总成交额比17.49%。 分红方面，信立泰A股上市后累计派现 ...

资料显示，哈尔滨三联药业股份有限公司位于黑龙江省哈尔滨市利民开发区北京路，成立日期1996年6 月21日，上市日期2017年9月22日，公司主营业务涉及化学药品制剂的研发、生产和销售。主营业务收 入构成为：大输液32.00%，冻干粉针剂18.39%，固体制剂17.39%，小容量注射剂14.34%，其他(补 充)10.26%，兽药2.55%，进出口贸易1.82%，原料药1.73%，化妆品0.94%，医疗器械0.43%，功能食品 0.16%。 哈三联所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：高血压防治、抗流感、肝 炎治疗、创新药、宠物经济等。 12月18日，哈三联盘中上涨2.10%，截至13:41，报13.15元/股，成交4103.33万元，换手率1.81%，总市 值41.60亿元。 资金流向方面，主力资金净流入46.33万元，大单买入354.33万元，占比8.64%，卖出308.00万元，占比 7.51%。 哈三联今年以来股价涨36.27%，近5个交易日跌1.79%，近20日跌4.29%，近60日跌4.15%。 今年以来哈三联已经9次登上龙虎榜，最近一次登上龙虎榜为6月3日。 截至12月1 ...